India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...

Indian drugmakers have launched affordable generic versions of popular diabetes and weight-loss drugs. This move significantly reduces trea...

Glenmark Pharmaceuticals is set to launch affordable versions of the popular anti-diabetes and obesity drug semaglutide. This move escalate...

Sharvil Patel is the new president of the Indian Pharmaceutical Alliance. He takes over from Samir Mehta. Glenn Saldanha becomes the vice p...

Some of these PE-owned platform companies include Advent International-led Cohance Lifesciences / Suven Pharma, PAG and CX Partners-funded ...

The company posted a consolidated net loss, from continuing operations, of 2.01 billion rupees ($24.14 million) for the three months ended ...

Eris Lifesciences has announced that it has reached a definitive agreement to acquire the dermatology and nephrology branded formulations b...

The healthcare sector's impressive performance in the stock market highlights these companies' commitment to innovation, research, and deli...

It has been aiming to reduce its debt, including through the sale of some dermatology brands to Eris Lifesciences for Rs 3,400 crore in Jan...

The transaction will be financed through borrowings and will achieve financial closure in the next few days, the drug firm said. In a separ...

The nine brands have sales of Rs 87.30 crores for FY22, which represents valuation of 3.9x of the sales of these brands in FY22. The acquir...

The deal for the portfolio that has an annual revenue base of 850 million rupees, will be financed through borrowings, and the transaction ...

The deal, through Eris' dermatology focused unit, is for the purchase of nine brands, including Onabet, Halobate, Sorvate, and Demelan for ...

Consolidated revenues of the drug firm, however, rose to Rs 3,019 crore in the quarter under review as compared to Rs 2,860 crore in the ye...

In 2020, 16 issues had mopped up Rs 26,628 crore, and a similar number of IPOs had collected Rs 12,687 crore in 2019, but 2018 was the best...

At least 12 drug makers and healthcare companies are planning IPOs in 2021 as the pandemic increases investor demand for the promising play...

Indian drug makers may be receiving an increasing number of approvals from the USFDA for drug launches in the United States.